Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Protara Therapeutics ( (TARA) ) has provided an announcement.
On March 30, 2026, Protara Therapeutics reported updated data from its ongoing Phase 2 ADVANCED-2 trial of TARA-002 in Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, confirming a six-month complete response rate of 68.0% in the first 25 such patients, in line with results disclosed in February 2026 and substantially above the 41.9% benchmark. Based on achieving this efficacy threshold, the company determined that a key condition embedded in common stock purchase warrants issued in April 2024 had been satisfied, fixing the warrants’ exercise window and cementing a path for potential additional capital inflows ahead of their June 29, 2026 expiration.
The most recent analyst rating on (TARA) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Protara Therapeutics stock, see the TARA Stock Forecast page.
Spark’s Take on TARA Stock
According to Spark, TipRanks’ AI Analyst, TARA is a Neutral.
The score is held down mainly by weak financial performance (no revenue, recurring losses, and ongoing cash burn) and soft technicals (price below key moving averages with negative MACD). Offsetting these are constructive corporate developments (positive Phase 2 update and clearer registrational path) and a stronger, low-debt balance sheet, while valuation support is limited due to negative earnings and no dividend.
To see Spark’s full report on TARA stock, click here.
More about Protara Therapeutics
Protara Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic candidates for patients with cancer, including non-muscle invasive bladder cancer. Its pipeline includes TARA-002, an investigational therapy being evaluated in the ADVANCED-2 Phase 2 open-label trial for patients with carcinoma in situ, with or without Ta/T1 disease, who are unresponsive to Bacillus Calmette-Guérin.
Average Trading Volume: 1,142,141
Technical Sentiment Signal: Hold
Current Market Cap: $267.2M
For detailed information about TARA stock, go to TipRanks’ Stock Analysis page.